Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice

Journal of Sexual Medicine

Volumn 7, Issue 1 PART 1, 2010, Pages 277-283

  Rhoden, Ernani Luis ^a,b   Morgentaler, Abraham ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

Aging; Free testosterone; Hypogonadism; Testosterone replacement therapy; Testosterone treatment for hypogonadism; Total testosterone levels

Indexed keywords

SILDENAFIL; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE;

ADULT; AGED; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ARTICLE; CLINICAL PRACTICE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; GYNECOMASTIA; HEMATOCRIT; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIBIDO; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOOD; PENIS ERECTION; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOM; TREATMENT DURATION;

EID: 74049143811     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01544.x     Document Type: Article

References (24)

1. Morley JE, Kaiser FE, Perry HM, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ. Longitudinal changes in testosterone, LH and FSH in healthy older men. Metabolism 1997, 46:410-3.
2. Anawalt BD, Merriam GR. Neuroendocrine aging in men. Andropause and somatopause. Endocrinol Metabol Clin N Am 2001, 30:647-69.
3. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore longitudinal study of aging. J Clin Endocrinol Metab 2001, 86:724-31. Baltimore Longitudinal Study of Aging
4. Zmuda JM, Cauley J and Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factor in middle-aged men: A 13-year follow-up of former multiple factor intervention trial participants. Am J Epidemiol 1997, 146:609-17.
5. Hintikka J, Niskanen L, Koivumaa-Honkanen H, Tolmunen T, Honkalampi K, Lehto SM, Viinamäki H. Hypogonadism, decreased sexual desire, and long-term depression in middle-aged men. J Sex Med 2009, 6:2049-57. Epub 2009 Apr 28
6. Tenover JL. Male hormone replacement therapy including " andropause. Endocrinol Metabol Clin N Am 1998, 27:969-87.
7. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000, 85:2670-7.
8. Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial. J Clin Endocrinol Metab 1997, 82:1661-7.
9. Snyder PJ, Peachey H, Berlin JA, Rader D, Usher D, Loh L, Hannoush P, Dlewati A, Holmes JH, Santanna J, Strom BL. Effects of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am J Med 2001, 111:255-60.
10. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001, 56:M266-72.
11. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999, 84:3469-78.
12. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG, Strom BL. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999, 84:1966-72.
13. Crawford ED, Barqawi AB, O'Donnell C, Morgentaler A. The association of time of day and serum testosterone concentration in a large screening population. Br J Urol 2007, 100:509-13.
14. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006, 91:1995-2010.
15. Morgentaler A. Commentary: Guidelines for male testosterone therapy: a clinician's perspective. J Clin Endocrinol Metab 2007, 92:416-7.
16. Zitzmann M, Nieschlag E. Hormone substitution in male hypogonadism. Mol Cell Endocrinol 2000, 161:73-88.
17. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunnigham G, Matsumoto AM, Weber T, Berman T. Transdermal testosterone gel improves sexual function,mood, mucsle strength, and body composition parameters in hypogondal men. J Clin Endocrinol Metab 2000, 85:2839-53.
18. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in hypogondal males: A retrospective analysis. J Clin Endocrinol Metab 1997, 82:3793-6.
19. Reyes-Vallejo L, Lazarou S, Morgentaler A. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone. J Sex Med 2007, 4:1757-62.
20. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84:3666-72.
21. Okamura K, Ando F, Shimokata H. Serum total and free testosterone level of Japanese men: A population-based study. Int J Urol 2005, 12:810-4.
22. Moreno SA, Shyam A, Morgentaler A. Comparison of free testosterone results by analog radioimmunoassay and calculated free testosterone in an ambulatory clinical population. J Sex Med 2009, Sep 1 [Epub ahead of print] doi:10.1111/j.1743-6109.2009.01473.x
23. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less. Urology 2006, 68:1263-7.
24. Moreno SA, Morgentaler A. Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship. J Sex Med 2009, 6:1729-35.